Closed System Transfer Devices

Featured Partner: Equashield

equashield

EQUASHIELD®  is an innovative closed system transfer device (CSTD) for the safe handling of hazardous drugs, especially for the compounding and administering of hazardous drugs according to the NIOSH definition of an airtight and leakproof closed system transfer device.

White Papers

Equashield White Papers
Read More

More White Papers (coming)

Articles

Read More

References for Closed System Transfer Devices

American Society of Health System Pharmacists Council on Professional Affairs. ASHP Guidelines on Handling Hazardous Drugs. Am J Health-Syst Pharm. 2006;63:1172-1193.

Centers for Disease Control and Prevention. National Institute for Occupational Safety and Health. Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. http://www.cdc.gov/niosh/docs/2004-165/. Accessed June 16, 2015.

Clark BA, Sessink PJ. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents. J Oncol Pharm Pract. 2013;19(2):99-104.   (posted on Equashield.com)

Connor TH, Anderson RW, Sessink PJ, et al. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health-Syst Pharm. 2002;59(1):68-72.

Fouzia Berdi, PharmD, Michael F Powell, Christine Sanz, RPh, Richard Gonzalez, PharmD, MBA, Firouzan Massoomi, PharmD, FASHP. Assessing the Efficiency of CSTDs for Compounding. July 2015:Hazardous Drug Handling Supplement. Pharm,Purch,&Prod.2015;12(7):S4-S10

Harrison BR, Peters BG, Bing MR. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health-Syst Pharm. 2006;63(18):1736-1744.

Kicenuik K, Northrup N, Dawson A, et al. Treatment time, ease of use and cost associated with use of Equashield™, PhaSeal®, or no closed system transfer device for administration of cancer chemotherapy to a dog model [published online ahead of print April 10, 2015]. Vet Comp Oncol. doi: 10.1111/vco.12148.

Knolla K, Greisen D, Massoomi F. Time and motion study of 5 closed system transfer devices for IV chemotherapy drug compounding and administration. Poster presented at: American Society of Health-System Pharmacists Clinical Midyear Meeting; December 2011; New Orleans, Louisiana.

Lamm MH, Eckel S, Daniels R, Amerine LB. Using lean principles to improve outpatient adult infusion clinic chemotherapy preparation turnaround times. Am J Health-Syst Pharm. 2015;72(13):1138-1146.

Nyman H, Jorgenson J, Slawson MH. Workplace contamination with antineoplastic agents in a new cancer hospital using a closed-system drug transfer device. Hosp Pharm. 2007;42:219-225.

Sessink PJM, Connor TH, Jorgenson JA, Tyler TG. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Pract. 2011;17(1):39-48.

Sessink PJM, Rolf ME, Ryden NS. Evaluation of the PhaSeal Hazardous Drug Containment System. Hosp Pharm. 1999;34:1311-1317.

Smith ST,Szlaczky MC.Syringe plunger contamination by hazardous drugs: A comparative study.J Oncol Pharm Pract. October 2014;20:381-385,first published on March 5, 2014    (posted at Equashield.com)

Spivey S, Connor TH. Determination of sources of workplace contamination with antineoplastic drugs and comparison of conventional IV drug preparation versus a closed system. Hosp Pharm. 2003;38:135-139.

United States Pharmacopeial Convention. General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings. http://www.usp.org/usp-nf/notices/general-chapter-hazardous-drugs-handling-healthcare-settings. Accessed June 16, 2015.

Wick C, Slawson MH, Jorgenson JA, et al. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health-Syst Pharm. 2003;60(22):2314-2320.

FAQs for CSTDs

Does using a CSTD increase the amount of time it takes to compound an IV?

It is believed that properly trained staff that are experienced with using CSTDs require about the same amount of time as it takes with a needle and syringe. (Fouzia Berdi, PharmD, Michael F Powell, Christine Sanz, RPh, Richard Gonzalez, PharmD, MBA, Firouzan Massoomi, PharmD, FASHP. Assessing the Efficiency of CSTDs for Compounding. July 2015:Hazardous Drug Handling Supplement. Pharm,Purch,&Prod.2015;12(7):S4-S10)

Send us your FAQs to post in this section.

WHERE TO FIND: Closed System Drug-Transfer Devices (CSTDs)

Allison Medical, Inc
B. Braun Medical Inc
BD
CareFusion
Equashield LLC
ICU Medical, Inc

 

Please follow and like us:

Get new posts by email:
Social media & sharing icons powered by UltimatelySocial